gemcitabine + cisplatin + radiotherapy

The GEMCIRAV regimen is a concurrent chemoradiotherapy protocol developed and evaluated by the Institut du Cancer de Montpellier - Val d'Aurelle for the treatment of muscle-invasive bladder cancer (MIBC). This combination therapy consists of gemcitabine hydrochloride, a pyrimidine antimetabolite that inhibits DNA synthesis, and cisplatin, a platinum-based chemotherapy agent that induces DNA cross-linking, administered alongside daily radiotherapy. The regimen is designed as a bladder-preservation strategy for patients with Stage II or III transitional cell carcinoma of the bladder. In the Phase I/II GEMCIRAV clinical trial (NCT00556621), gemcitabine was administered intravenously twice weekly for five weeks, while cisplatin was given as a continuous infusion during the first and fourth weeks of the radiotherapy course. Long-term results from the study demonstrated significant efficacy, with a 5-year overall survival rate of 62%.

Brand names

Gemzar

Other names

gemcitabine hydrochloridecisplatinradiation therapyconcurrent chemoradiotherapy